Literature DB >> 3632393

Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone.

M H Brooke, G M Fenichel, R C Griggs, J R Mendell, R T Moxley, J P Miller, K K Kaiser, J M Florence, S Pandya, L Signore.   

Abstract

We investigated the effect of high-dose prednisone therapy in 33 boys with Duchenne muscular dystrophy. The drug was given daily in doses of 1.5 mg/kg of body weight (to a maximum of 80 mg) for six months. Muscle strength, joint contractures, timed functional tests, functional ability, and pulmonary function were measured at the beginning and end of the treatment period. The trial was designed using natural history controls, and the power of the study was 0.80 to detect a slowing of 50% in the rate of progression. During the period of the trial, muscle strength, functional grades, timed functional tests, and pulmonary function improved. Contractures followed the expected natural history of the illness.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3632393     DOI: 10.1001/archneur.1987.00520200016010

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  35 in total

Review 1.  Muscular dystrophies.

Authors:  L Specht
Journal:  Indian J Pediatr       Date:  1990 May-Jun       Impact factor: 1.967

2.  Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.

Authors:  Luca Bello; Heather Gordish-Dressman; Lauren P Morgenroth; Erik K Henricson; Tina Duong; Eric P Hoffman; Avital Cnaan; Craig M McDonald
Journal:  Neurology       Date:  2015-08-26       Impact factor: 9.910

3.  A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy.

Authors:  Kristin J Krosschell; Jo Anne Maczulski; Thomas O Crawford; Charles Scott; Kathryn J Swoboda
Journal:  Neuromuscul Disord       Date:  2006-06-05       Impact factor: 4.296

4.  The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies.

Authors:  Mahmoud R Hussein; Sherifa A Hamed; Mohammed G Mostafa; Eman E Abu-Dief; Nageh Fouly Kamel; Mahmoud R Kandil
Journal:  Int J Exp Pathol       Date:  2006-12       Impact factor: 1.925

5.  Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy.

Authors:  D M Escolar; L P Hache; P R Clemens; A Cnaan; C M McDonald; V Viswanathan; A J Kornberg; T E Bertorini; Y Nevo; T Lotze; A Pestronk; M M Ryan; E Monasterio; J W Day; A Zimmerman; A Arrieta; E Henricson; J Mayhew; J Florence; F Hu; A M Connolly
Journal:  Neurology       Date:  2011-07-13       Impact factor: 9.910

Review 6.  Immunobiology of Inherited Muscular Dystrophies.

Authors:  James G Tidball; Steven S Welc; Michelle Wehling-Henricks
Journal:  Compr Physiol       Date:  2018-09-14       Impact factor: 9.090

Review 7.  The muscular dystrophies: from genes to therapies.

Authors:  Richard M Lovering; Neil C Porter; Robert J Bloch
Journal:  Phys Ther       Date:  2005-12

8.  Steroid therapy and cardiac function in Duchenne muscular dystrophy.

Authors:  L W Markham; R L Spicer; P R Khoury; B L Wong; K D Mathews; L H Cripe
Journal:  Pediatr Cardiol       Date:  2005 Nov-Dec       Impact factor: 1.655

9.  Decrease in urinary excretion of 3-methylhistidine by patients with Duchenne muscular dystrophy during glucocorticoid treatment.

Authors:  H Kawai; K Adachi; Y Nishida; T Inui; C Kimura; S Saito
Journal:  J Neurol       Date:  1993       Impact factor: 4.849

10.  The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used.

Authors:  Craig M McDonald; Erik K Henricson; R Ted Abresch; Jay J Han; Diana M Escolar; Julaine M Florence; Tina Duong; Adrienne Arrieta; Paula R Clemens; Eric P Hoffman; Avital Cnaan
Journal:  Muscle Nerve       Date:  2013-05-16       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.